Edition:
United Kingdom

Dova Pharmaceuticals Inc (DOVA.OQ)

DOVA.OQ on NASDAQ Stock Exchange Global Market

15.13USD
4:46pm BST
Change (% chg)

$-0.21 (-1.37%)
Prev Close
$15.34
Open
$15.47
Day's High
$15.70
Day's Low
$15.04
Volume
19,327
Avg. Vol
93,175
52-wk High
$26.49
52-wk Low
$5.62

Latest Key Developments (Source: Significant Developments)

Dova Pharmaceuticals Reports Second Quarter 2019 Operating And Financial Results
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS REPORTS SECOND QUARTER 2019 OPERATING AND FINANCIAL RESULTS.Q2 2019 NET SALES FROM DOPTELET OF $3.5 MILLION.QTRLY PRESCRIPTION REFERRALS INCREASED APPROXIMATELY 7% COMPARED TO Q1.SALES WERE NEGATIVELY AFFECTED BY COMPETITIVE PRICING PRESSURE AND PAYER RESTRICTIONS IN Q2 OF 2019.  Full Article

Dova Pharmaceuticals Announces FDA Approval Of Supplemental New Drug Application For Doptelet For Treatment Of Chronic Immune Thrombocytopenia
Thursday, 27 Jun 2019 

June 27 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR DOPTELET® (AVATROMBOPAG) FOR TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA (ITP).DOVA PHARMACEUTICALS INC - EXPANDED PARTNERSHIP WITH SALIX FOR CHRONIC LIVER DISEASE (CLD) INDICATION.DOVA PHARMACEUTICALS INC - COMMERCIAL LAUNCH OF DOPTELET FOR ITP IS ANTICIPATED TO OCCUR IN MID-JULY 2019.DOVA PHARMACEUTICALS - SALIX WILL HAVE EXCLUSIVE RIGHT TO CO-PROMOTE CLD INDICATION FOR DOPTELET TO HEPATOLOGY AND INTERVENTIONAL RADIOLOGY SEGMENTS.DOVA PHARMACEUTICALS INC - DOVA WILL CONTINUE TO PAY SALIX A COMMISSION BASED ON A PERCENTAGE OF NET SALES IN SPECIFIED SPECIALTIES.DOVA PHARMACEUTICALS INC - CO-PROMOTION AGREEMENT WITH SALIX WAS EXTENDED TO SEPTEMBER 2023..DOVA PHARMACEUTICALS INC - EXPECT DOPTELET'S PHASE 3 TRIAL TOP-LINE RESULTS IN FIRST HALF OF 2020.  Full Article

Dova Pharma Announces EU Marketing Authorization For Doptelet For The Treatment Of Thrombocytopenia In Patients With Chronic Liver Disease
Tuesday, 25 Jun 2019 

June 25 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS ANNOUNCES EUROPEAN UNION MARKETING AUTHORIZATION FOR DOPTELET® (AVATROMBOPAG) FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC LIVER DISEASE.APPROVAL BASED ON POSITIVE EFFICACY AND SAFETY DATA FROM TWO PHASE 3 CLINICAL TRIALS.INTENDS TO PARTNER FOR EUROPEAN COMMERCIALIZATION OF DOPTELET.DOVA PHARMACEUTICALS - MARKETING AUTHORIZATION APPLIES TO ALL 28 EUROPEAN UNION MEMBER STATES PLUS ICELAND, NORWAY, AND LIECHTENSTEIN.  Full Article

Dova Pharmaceuticals Says Net Product Sales For Doptelet Were $4 Mln For Q1
Tuesday, 7 May 2019 

May 7 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS REPORTS FIRST QUARTER 2019 OPERATING AND FINANCIAL RESULTS.NET PRODUCT SALES FOR DOPTELET WERE $4.0 MILLION FOR Q1, AN INCREASE OF 43% FROM Q4 OF 2018.EARLY IN Q2, A NEW MARKETING STRATEGY WAS LAUNCHED.FROM LAUNCH THROUGH MARCH 31, 2019, A TOTAL OF 1,060 HEALTH CARE PROFESSIONALS HAVE PRESCRIBED DOPTELET TO THEIR PATIENTS.DOVA PHARMACEUTICALS - INVENTORY HELD BY SPECIALTY PHARMACIES IN DOVA'S CONTRACTED NETWORK REMAINED RELATIVELY CONSTANT FROM JANUARY 1, TO MARCH 31.QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.58.  Full Article

Dova Pharmaceuticals Qtrly Loss Per Share $0.69
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 OPERATING AND FINANCIAL RESULTS.DOVA PHARMACEUTICALS INC - NET PRODUCT SALES FROM DOPTELET WERE $2.8 MILLION IN Q4 OF 2018.DOVA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.69.  Full Article

Dova Pharmaceuticals announces FDA acceptance of supplemental new drug application for Doptelet (Avatrombopag) for treatment of chronic immune thrombocytopenia (Itp)
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR DOPTELET (AVATROMBOPAG) FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA (ITP).DOVA PHARMACEUTICALS INC - PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE FOR AN FDA DECISION ON SNDA IS JUNE 30, 2019..  Full Article

Dova Pharmaceuticals Announces U.S. FDA Approval Of Doptelet
Monday, 21 May 2018 

May 21 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS ANNOUNCES U.S. FDA APPROVAL OF DOPTELET® (AVATROMBOPAG).DOVA PHARMACEUTICALS INC - POSITIONED TO LAUNCH DOPTELET IN JUNE.  Full Article

FDA Approves Dova Pharma's New Drug For Patients With CLD Who Have Low Blood Platelets
Monday, 21 May 2018 

May 21 (Reuters) - U.S. FDA::FDA APPROVES NEW DRUG FOR PATIENTS WITH CHRONIC LIVER DISEASE WHO HAVE LOW BLOOD PLATELETS AND ARE UNDERGOING A MEDICAL PROCEDURE.FDA SAYS THE FDA GRANTED THE APPROVAL TO AKARX INC.  Full Article

Dova Pharmaceuticals Signs Distribution Agreement With Fosun Pharma For Mainland China And Hong Kong
Monday, 19 Mar 2018 

March 19 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT WITH FOSUN PHARMA FOR MAINLAND CHINA AND HONG KONG.DOVA PHARMACEUTICALS - ‍DEAL THROUGH UNIT GRANTING FOSUN PHARMA EXCLUSIVE DEVELOPMENT,DISTRIBUTION RIGHTS OF AVATROMBOPAG IN MAINLAND CHINA, HONG KONG​.DOVA PHARMACEUTICALS INC - ‍TERMS OF TRANSACTION INCLUDE AN UPFRONT PAYMENT, MILESTONE PAYMENTS, AND A FIXED TRANSFER PRICE FOR PRODUCT SUPPLIED​.  Full Article

Dova Pharmaceuticals Says Public Offering Of 2.50 Mln Shares Priced At $32 per Share
Friday, 23 Feb 2018 

Feb 22 (Reuters) - Dova Pharmaceuticals Inc ::DOVA PHARMACEUTICALS, INC. ANNOUNCES PRICING OF OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 2.50 MILLION COMMON SHARES PRICED AT $32.00 PER SHARE.  Full Article